In collaboration with the Medina Group are examining fundamental roles of glycoproteins in cancer cell biology facilitated by a newly discovered glycan-binding protein (Lectin-1) that kills epithelial cancer cells with unprecedented potency (picomolar concentration). Utilizing chemical biology, evolution, genomics and cancer biology, we are studying the affinity and specificity of this new anti-tumor lectin, as well as selected candidates from a library of novel lectins, toward cancer-associated glycans and characterizing mechanisms of their cytotoxic action.
Jim Marden | Biology / Biomedical Engineering, Scott Medina | Biology / Biomedical Engineering